(UTHR) United Therapeutics Corporation – Bull of the Day

United Therapeutics Corp.’s (UTHR) second quarter earnings of $1.43 per share were well above the year-ago earnings of $1.19 and the Zacks Consensus Estimate of $1.12. Higher revenues led to the improvement in earnings. The company maintained its guidance for 2012.

We believe the company is well-positioned to gain share in the pulmonary arterial hypertension (PAH) market. Lead product Remodulin continues to look very strong in both the intravenous (IV) and subcutaneous (SC) forms. With the approval of Adcirca and Tyvaso, the company has a varied range of therapies available for the treatment of PAH.

We believe the company’s PAH product portfolio will drive strong top-and bottom-line growth. We maintain our Outperform recommendation on United Therapeutics, which carries a Zacks #2 Rank (short-term Buy rating).

Zacks Investment Research

About vitalstocks

This is a sample profile field. Vitalstocks is the operating company for Stockbloghub. This will place the picture of the author or company in the profile. Here is another extra line of information.

Comments

Powered by Facebook Comments


Similar Posts: | | Drug Manufacturers - Other | Healthcare

RSS feeds: United Therapeutics Corporation | UTHR | Drug Manufacturers - Other | Healthcare |

Other Posts by | RSS Feed for this author